244
Participants
Start Date
October 30, 2024
Primary Completion Date
October 30, 2028
Study Completion Date
October 30, 2029
Avastin, 25 Mg/mL Intravenous Solution
"Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity."
CHU DE BESANCON
UNKNOWN
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
CHU de Clermont-Ferrand
UNKNOWN
CHU de Reims
OTHER
CHU de Brest
UNKNOWN
AP-HP, Hôpital Pitié- Salpétrière
UNKNOWN
University Hospital, Rouen
OTHER
Poitiers University Hospital
OTHER
Institut Paoli-Calmettes
OTHER
Rennes University Hospital
OTHER
University Hospital, Toulouse
OTHER
AP-HP, Hôpital Saint-Louis
UNKNOWN
HCL Hôpital Edouard Hériot
UNKNOWN
Centre Hospitalier Universitaire Dijon
OTHER
Nantes University Hospital
OTHER
Centre Hospitalier Universitaire, Amiens
OTHER
Hôpital Privé Jean Mermoz
UNKNOWN
AP-HP, Hôpital Henri Mondor
UNKNOWN
AP-HP, Hôpital Paul Brousse
UNKNOWN
CHG de St-Malo
UNKNOWN
Polyclinique de Blois
UNKNOWN
University Hospital, Caen
OTHER
Central Hospital, Nancy, France
OTHER
University Hospital, Tours
OTHER